Biotech

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) announced that a sixth patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at the Barnes-Jewish Hospital at Washington University Medical Center in St. Louis, Missouri.

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) announced that a sixth patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at the Barnes-Jewish Hospital at Washington University Medical Center in St. Louis, Missouri.
According to the news:

Wilson (Zack) Ray, M.D., Associate Professor of Neurosurgery and a member of The INSPIRE Study Steering Committee, performed the implantation approximately 10 hours after the injury occurred. Paul Santiago, M.D., is the Principal Investigator at this site.

Dr. Ray commented:

We were able to get the patient into the operating room in such an expeditious manner thanks to the experienced trauma and neurosurgical teams at the Barnes-Jewish Hospital. The implantation procedure was straightforward and the patient is recovering well. I look forward to following the patient’s progress.

Click here to view the full press release. 

Featured

MARKETS

Markets
TSX20197.61+15.69
TSXV702.09-3.49
DOW31880.24+618.34
S&P 5003973.75+72.39
NASD11535.27+180.66
ASX7148.90+3.30

COMMODITIES

Commodities
Gold1858.51+4.84
Silver21.88+0.14
Copper4.32-0.03
Palladium2018.45+33.45
Platinum958.38+5.38
Oil109.62-0.67
Heating Oil3.63-0.02
Natural Gas8.78+0.03

DOWNLOAD FREE REPORTS

×